|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
|
|
Tramadol for osteoarthritisCepeda MS, Camargo F, Zea C, Valencia L
Bookmark this:
loading... please wait
SummaryTramadol for osteoarthritisThis summary of a Cochrane review presents what we know from research about the effect of tramadol for osteoarthritis. The review shows that:There is gold level evidence that to treat osteoarthritis, tramadol taken for up to three months may decrease pain, may improve stiffness and function and overall-well being. Tramadol may cause side effects such as nausea, vomiting, dizziness, constipation, tiredness, and headache. The benefits of tramadol are small and the side effects may cause people to stop taking it which may limit how useful tramadol is to treat osteoarthritis.
What is osteoarthritis and what drugs are used to treat it?
What are the results of this review?
Benefits of tramadol
- 69 out of 100 people may improve when taking tramadol
It is not known whether tramadol improves symptoms of osteoarthritis more than other drugs. It is also not known whether tramadol still works well after long use. This is because the follow -up of the studies was short.
Harms of tramadol
- 39 out of 100 people may have minor side effects when taking tramadol
- 21 out of 100 people had major side effects when taking tramadol It is not known whether tramadol causes more side effects than other drugs for osteoarthritis.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2008 Issue 2, Copyright © 2008 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
July 19. 2006 AbstractBackgroundTramadol is increasingly used for the treatment of osteoarthritis because, in contrast to nonsteroidal anti-inflammatory drugs (NSAIDs), tramadol does not produce gastrointestinal bleeding or renal problems, and does not affect articular cartilage. ObjectivesWe sought to determine the analgesic effectiveness, the effect on physical function, the duration of benefit and the safety of oral tramadol in people with osteoarthritis. Search strategyWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS databases up to August 2005. Selection criteriaWe included randomized controlled trials (RCTs) that evaluated the effect of tramadol or tramadol plus paracetamol on pain levels and/or physical function in people with osteoarthritis. No language restriction was applied. Data collection and analysisWe analyzed separately placebo-controlled and active-controlled studies. We used fixed-effect models for the meta-analyses as the results across studies were similar. Main resultsWe included eleven RCTs with a total of 1019 participants who received tramadol or tramadol/paracetamol and 920 participants who received placebo or active-control. The placebo-controlled studies indicated that participants who received tramadol had less pain (-8.5 units on a 0 to 100 scale; 95% confidence interval (CI) -12.0 to -5.0) than patients who received placebo. This represents a 12% relative decrease in pain intensity from baseline. Participants who received tramadol had a 37% increase (95% CI 1.2 to 1.5) in the likelihood of reporting moderate improvement (number needed to treat to benefit = 6; 95% CI 4 to 9). Participants who received tramadol had 2.27 times the risk of developing minor adverse events and 2.6 times the risk of developing major adverse events, compared to participants who received placebo. Of every eight people who receive tramadol or tramadol/paracetamol, one will stop taking the medication because of adverse events, number needed to treat to harm (NNTH)= 8 (95% CI 7 to 12) for major adverse events. No conclusion could be drawn on how tramadol or tramadol/paracetamol compared with available pharmacological treatments because of the limited number of studies that evaluated such therapies. Authors' conclusionsTramadol or tramadol/paracetamol decreases pain intensity, produces symptom relief and improves function, but these benefits are small. Adverse events, although reversible and not life threatening, often cause participants to stop taking the medication and could limit tramadol or tramadol plus paracetamol usefulness. |